miRNA作為乙型和丙型病毒性肝炎的潛在生物標誌物

StephenW

miRNAs as Potential Biomarkers for Viral Hepatitis B and C
Dimitri Loureiro  1 , Issam Tout  1 , Stéphanie Narguet  1 , Sabrina Menasria Benazzouz  1 , Abdellah Mansouri  1 , Tarik Asselah  1
Affiliations
Affiliation

    1
    Department of Hepatology, Université de Paris, CRI, INSERM UMR 1149, AP-HP Hôpital Beaujon, 92110 Clichy, France.

    PMID: 33327640 DOI: 10.3390/v12121440

Abstract

Around 257 million people are living with hepatitis B virus (HBV) chronic infection and 71 million with hepatitis C virus (HCV) chronic infection. Both HBV and HCV infections can lead to liver complications such as cirrhosis and hepatocellular carcinoma (HCC). To take care of these chronically infected patients, one strategy is to diagnose the early stage of fibrosis in order to treat them as soon as possible to decrease the risk of HCC development. microRNAs (or miRNAs) are small non-coding RNAs which regulate many cellular processes in metazoans. Their expressions were frequently modulated by up- or down-regulation during fibrosis progression. In the serum of patients with HBV chronic infection (CHB), miR-122 and miR-185 expressions are increased, while miR-29, -143, -21 and miR-223 expressions are decreased during fibrosis progression. In the serum of patients with HCV chronic infection (CHC), miR-143 and miR-223 expressions are increased, while miR-122 expression is decreased during fibrosis progression. This review aims to summarize current knowledge of principal miRNAs modulation involved in fibrosis progression during chronic hepatitis B/C infections. Furthermore, we also discuss the potential use of miRNAs as non-invasive biomarkers to diagnose fibrosis with the intention of prioritizing patients with advanced fibrosis for treatment and surveillance.

Keywords: anti-fibrogenic; chronic hepatitis; chronic liver diseases; diagnosis; fibrosis markers; inflammation; liver; pro-fibrogenic.

StephenW

miRNA作為乙型和丙型病毒性肝炎的潛在生物標誌物
Dimitri Loureiro 1，Issam Tout 1，StéphanieNarguet 1，Sabrina Menasria Benazzouz 1，Abdellah Mansouri 1，Tarik Asselah 1
隸屬關係
聯繫

    1個
    巴黎大學巴黎分校肝病科，INSERM UMR 1149，AP-HPHôpitalBeaujon，92110克利希，法國。

    PMID：33327640 DOI：10.3390 / v12121440

抽象

大約2.57億人患有乙型肝炎病毒（HBV）慢性感染，7100萬人患有丙型肝炎病毒（HCV）慢性感染。 HBV和HCV感染均可導致肝臟並發症，例如肝硬化和肝細胞癌（HCC）。為了照顧這些慢性感染的患者，一種策略是診斷纖維化的早期階段，以便儘早治療以降低HCC發生的風險。 microRNA（或miRNA）是小的非編碼RNA，可調節後生動物的許多細胞過程。它們的表達經常在纖維化進展過程中通過上調或下調來調節。在HBV慢性感染（CHB）患者的血清中，在纖維化進程中，miR-122和miR-185的表達升高，而miR-29，-143，-21和miR-223的表達則降低。在HCV慢性感染（CHC）患者的血清中，在纖維化進程中，miR-143和miR-223的表達增加，而miR-122的表達則減少。這篇綜述旨在總結當前在慢性乙型/丙型肝炎感染過程中參與纖維化進程的主要miRNA調控的知識。此外，我們還討論了將miRNA用作非侵入性生物標記物以診斷纖維化的潛在用途，目的是優先考慮晚期纖維化患者進行治療和監測。

關鍵詞：抗纖維化；抗纖維化慢性肝炎慢性肝病診斷;纖維化標記炎;肝;促成纖維的。

StephenW

https://www.mdpi.com/1999-4915/12/12/1440/pdf